Myriad Genetics Sees FY24 Adj. EPS $0.00-$0.05 Vs $0.02 Est.; Revenue $820M-$840M Vs $826.582M Est.
Portfolio Pulse from Benzinga Newsdesk
Myriad Genetics forecasts its FY24 adjusted EPS to be between $0.00 and $0.05, compared to the estimated $0.02. The company also projects its revenue to be in the range of $820M to $840M, versus the estimated $826.582M.
May 07, 2024 | 9:41 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Myriad Genetics forecasts a FY24 adjusted EPS of $0.00-$0.05, slightly above the $0.02 estimate, and revenue of $820M-$840M, around the $826.582M estimate.
The company's projected EPS range slightly surpasses the analyst estimate, indicating potential positive sentiment among investors. The revenue forecast closely matches analyst expectations, suggesting stability in the company's financial outlook. This combination of meeting and slightly exceeding analyst expectations could lead to a positive short-term impact on MYGN's stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100